Form 4: Health Catalyst COO Daniel LeSueur Sells Shares Under 10b5-1 Trading Plan

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 5,209 shares of common stock at a price of $5.7607 per share on February 5, 2025, under a pre-arranged trading plan.

Summary

• On February 5, 2025, Daniel LeSueur, the Chief Operating Officer of Health Catalyst, Inc. (HCAT), sold 5,209 shares of the company's common stock.
• The transaction was executed at a price of $5.7607 per share.
• Following the sale, LeSueur directly owns 86,044 shares of Health Catalyst common stock.
• The sale was conducted under a pre-arranged written trading plan adopted on March 7, 2024, in accordance with Rule 10b5-1.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-existing trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Sales by company executives are a normal part of corporate governance. The fact that this sale was executed under a 10b5-1 plan suggests it was pre-planned and not based on any immediate inside information.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Health Catalyst, HCAT, Daniel LeSueur, Chief Operating Officer, stock sale, Form 4, Rule 10b5-1, trading plan, insider trading